Naloxone treatment in opioid addiction: the risks and benefits

Bibliography

• BROWNSTEIN MJ: A brief history of opiates, opioid peptides and opioid receptors. Proc. Natl Acad. Sci. USA (1993) 90:5391-5393.
   PubMed Web of Science ®Google Scholar
• VOLKOW ND, LI TK: Drug addiction: the neurobiology of behaviour gone awry. Nat Rev. Neurosci. (2004) 5:963-970.
   PubMed Web of Science ®Google Scholar
• THIRION X, LAPIERRE V, MICALLEF J et al.: Buprenorphine presciption by general practitioners in a French region. Drug Alcohol Depend. (2002) 65:197-204.
   PubMed Web of Science ®Google Scholar
• CONTET C, KIEFFER BL, BEFORT K: Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. (2004) 14:370-378.
   PubMed Web of Science ®Google Scholar
• MATTHES HWD, MALDONADO R, SIMONIN F et al.: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature (1996) 383:819-823.
   PubMed Web of Science ®Google Scholar
• KREEK MJ, LAFORGE KS, BUTELMAN E: Pharmacotherapy of addictions. Nat. Rev. Drug Discov. (2002) 1:710-726.
   PubMed Web of Science ®Google Scholar
• KOOB GF: The neurocircuitry of addiction: Implications for treatment. Clin. Neurosci. Res. (2005) 5:89-101.
   Web of Science ®Google Scholar
• KOOB GF, LEMOAL M: Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. Nat. Neurosci. (2005) 8:1442-1444.
   PubMed Web of Science ®Google Scholar
• O’CONNOR PG, FIELLIN DA: Pharmacologic treatment of heroin-dependent patients. Ann. Intern. Med. (2000) 133:40-54.
   PubMed Web of Science ®Google Scholar
• GOWING L, ALI R, WHITE J: Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst. Rev. (2006) 1:CD002021.
   PubMedGoogle Scholar
• DAHAN A, YASSEN A, BIJL H et al.: Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesth. (2005) 94:825-834.
   PubMed Web of Science ®Google Scholar
• YASSEN A, OLOFSEN E, DAHAN A, DANHOF M: Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J. Pharmacol. Exp. Ther. (2005) 313:1136-1149.
   PubMed Web of Science ®Google Scholar
• GONZALEZ JP, BROGDEN RN: Naltrexone – a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs (1988) 35:192-213.
   PubMed Web of Science ®Google Scholar
• MARTIN WR: Naloxone. Ann. Intern. Med. (1976) 85:765-768.
   PubMed Web of Science ®Google Scholar
• KAUFMAN RD, GABATHULER ML, BELVILLE JW: Potency, duration of action and pA2 in man of intravenous naloxone measured by reversal of morphine-depressed respiration. J. Pharmacol. Exp. Ther. (1981) 219:156-162.
   PubMed Web of Science ®Google Scholar
• NGAI SH, BERKOWITZ BA, YANG JC, HEMPSTEAD J, SPECTOR S: Pharmacokinetics of naloxone in rats and in man – basis for its potency and short duration of action. Anesthesiology (1976) 44:398-401.
   PubMed Web of Science ®Google Scholar
• HANDAL KA, SCHAUBEN JL, SALAMONE FR: Naloxone. Ann. Emerg. Med. (1983) 12:438-445.
   PubMed Web of Science ®Google Scholar
• FLACKE JW, FLACKE WE, WILLIAMS GD: Acute pulmonary edema following naloxone reversal of high-dose morphine anesthesia. Anesthesiology (1977) 47:376-378.
   PubMed Web of Science ®Google Scholar
• MICHAELIS LL, HICKEY PR, CLARK TL et al.: Ventricular irritability associated with the use of naloxone. Ann. Thoracic Surg. (1974) 18:608-614.
   PubMedGoogle Scholar
• TANAKA GY: Hypertensive reaction to naloxone. JAMA (1974) 228:25-26.
   PubMed Web of Science ®Google Scholar
• OSTERWALDER JJ: Naloxone for intoxications with intravenous heroin and heroin mixtures – harmless or hazardous? J. Toxicol. Clin. Toxicol. (1996) 34:409-416.
   PubMed Web of Science ®Google Scholar
• BOYD JJ, KYTTA JV, AITTOMAKI JV, ROSENBERG PH, SEPPALA TA, RANDELL TT: Cardiovascular changes after naloxone administration in propofol-sedated piglets during opioid overdose. Acta Anaesthesiol. Scand. (2006) 50:1271-1276.
   PubMed Web of Science ®Google Scholar
• KAGAWA S, STAFFORD MJ, WAGGENER TB, SEVERINGHAUS JW: No effect of naloxone on hypoxia-induced ventilatory depression in adults. J. Appl. Physiol. (1982) 52:1030-1034.
   PubMed Web of Science ®Google Scholar
• GAL TJ: Naloxone reversal of buprenorphine-induced respiratory depression. Clin. Pharmacol. Ther. (1989) 45:66-71.
   PubMed Web of Science ®Google Scholar
• VAN DORP E, YASSEN A, SARTON E et al.: Naloxone reversal reversal of buprenorphine-induced respiratory depression. Anesthesiology (2006) 105:51-57.
   PubMed Web of Science ®Google Scholar
• GONZALEZ G, OLIVETO A, KOSTEN TR: Treatment of heroin (diamorphine) addiction – current approaches and future prospects. Drugs (2002) 62:1331-1343.
   PubMed Web of Science ®Google Scholar
• JOHANSSON BA, BERGLUND M, LINDGREN A: Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction (2006) 101:491-503.
   PubMed Web of Science ®Google Scholar
• GOLD CG, CULLEN DJ, GONZALES S, HOUTMEYERS D, DWYER MJ: Rapid opioid detoxification during general anesthesia. Anesthesiology (1999) 91:1639-1647.
   PubMed Web of Science ®Google Scholar
• WHITE JM, IRVINE RJ: Mechanisms of fatal opioid overdose. Addiction (1999) 94:961-972.
   PubMed Web of Science ®Google Scholar
• GOLDFRANK L, WEISMAN RS, ERRICK JK, LO MW: A dosing nomogram for continuous infusion intravenous naloxone. Ann. Emerg. Med. (1986) 15:566-570.
   PubMed Web of Science ®Google Scholar
• GADDIS GM, WATSON WA: Naloxone-associated patient violence – an overlooked toxicity. Ann. Pharmacother. (1992) 26:196-198.
   PubMed Web of Science ®Google Scholar
• STRANG J, POWIS B, BEST D et al.: Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction (1999) 94:199-204.
   PubMed Web of Science ®Google Scholar
• LENTON SR, HARGREAVES KM: Should we conduct a trial of ditributing naloxone to heroin users for peer administration to prevent fatal overdose? Med. J. Aust. (2000) 173:260-263.
   PubMed Web of Science ®Google Scholar
• DARKE S, HALL W: The distribution of naloxone to heroin users. Addiction (1997) 92:1195-1199.
   PubMed Web of Science ®Google Scholar
• BACA CT, GRANT KJ: Take-home naloxone to reduce heroin death. Addiction (2005) 100:1823-1831.
   PubMed Web of Science ®Google Scholar
• DETTMER K, SAUNDERS B, STRANG J: Take home naloxone and the prevention of fatal heroin overdose: two pilot schemes. Br. Med. J. (2001) 322:895-896.
   PubMed Web of Science ®Google Scholar
• GALEA S, WORTHINGTON N, MARKHAM PIPER T, NANDI VV, CURTIS M, ROSENTHAL DNM: Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in NYC. Addict. Behav. (2006) 31:907-912.
   PubMed Web of Science ®Google Scholar
• STRANG J, KELLEHER M, BEST D, MAYET S, MANNING V: Emergency naloxone for heroin overdose. Br. Med. J. (2006) 333:614-615.
   PubMed Web of Science ®Google Scholar
• SPORER KA: Strategies for preventing heroin overdose. Br. Med. J. (2003) 326:442-444.
   PubMed Web of Science ®Google Scholar
• GOWING LR, ALI RL: The place of detoxification in treatment of opioid dependence. Curr. Opin. Psychiatry (2006) 19:266-270.
   PubMed Web of Science ®Google Scholar
• COLLINS ED, KLEBER HD, WHITTINGTON RA, HEITLER NE: Anesthesia-assisted versus buprenorphine or clonidine-assisted heroin detoxification and naltrexone induction – a randomized trial. JAMA (2005) 294:901-913.
   Web of Science ®Google Scholar
• DE JONG CAJ, LAHEIJ RJF, KRABBE PFM: General anesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled trial. Addiction (2005) 100:206-215.
   PubMed Web of Science ®Google Scholar
• GOWING L, ALI R, WHITE J: Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst. Rev. (2006) 2:CD002022.
   Google Scholar
• GOWING L, FARRELL M, ALI R, WHITE J: Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst. Rev. (2004) 4:CD002024.
   Google Scholar
• O’BRIEN C, GREENSTEIN R, TERNES J, WOODY G: Clinical Pharmacology of narcotic antagonists. Ann. NY Acad. Sci. (1978) 311:232-240.
   PubMedGoogle Scholar
• VAN BRUSSEL GHA: Beperkte plaats van naltrexon bij de behandeling van opiaatverslaving. Ned. Tijdschr. Geneeskd (2001) 145:1452-1456.
   PubMed Web of Science ®Google Scholar
• JOHNSON RE, MCKAGH J: Buprenorphine and Naloxone for heroin dependence. Curr. Psychiatry Rep. (2000) 2:519-526.
   PubMedGoogle Scholar
• STOLLER KB, BIGELOW GE, WALSH SL, STRAIN EC: Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) (2001) 154:230-242.
   PubMed Web of Science ®Google Scholar
• FUDALA P, BRIDGE TP, HERBERT S et al.: Office based treatment of opiate addiction with a sublingual tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. (2003) 349:949-958.
   PubMed Web of Science ®Google Scholar
• FIELLIN DA, PANTALON MV, CHAWARSKI MC et al.: Counseling plus buprenorphine maintenance therapy for opioid dependence. N. Engl. J. Med. (2006) 355:365-374.
   PubMed Web of Science ®Google Scholar
• CORREIA CJ, WALSH SL, BIGELOW GE, STRAIN EC: Effects associated with double-blind omission of buprenorphine/naloxone over a 98 h period. Psychopharmacology (Berl) (2006) 189:297-306.
   PubMed Web of Science ®Google Scholar
• COMER SD, WALKER EA, COLLINS ED: Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin dependent volunteers. Psychopharmacology (Berl) (2005) 181:664-675.
   PubMed Web of Science ®Google Scholar
• MENDELSON J, JONES RT, WELM S et al.: Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine stabilized, opiate-dependent volunteers. Psychopharmacology (Berl) (1999) 141:37-46.
   PubMed Web of Science ®Google Scholar
• ROBINSON GM, DUKES PD, ROBINSON BJ, COOKE RR, MAHONEY GN: The misuse of buprenorphine and naloxone in Wellington, New Zealand. Drug Alcohol Depend. (1993) 33:81-86.
   PubMed Web of Science ®Google Scholar